Waters Stock Price, News & Analysis

Waters (NYSE:WAT) has announced its upcoming Investor Day scheduled for March 5th, 2025, in New York City, beginning at 8:30 AM ET. The event will showcase presentations from senior management, highlighting business achievements, strategic priorities, and future value creation plans, followed by a Q&A session.

The company is offering both in-person attendance and live webcast options, with registration available through the Waters Investor Relations website. A replay of the webcast will be accessible after the event concludes.

Waters is a global leader in analytical instruments and software, known for innovations in chromatography, mass spectrometry, and thermal analysis. The company employs approximately 7,500 people worldwide, operates in 35 countries with 15 manufacturing facilities, and distributes products in over 100 countries.

Waters (NYSE: WAT) has been named to the Dow Jones Sustainability North America Index (DJSI North America) for the fourth consecutive year, surpassing industry averages across all sustainability categories. The company achieved its greenhouse gas reduction target two years early in 2023 and made progress in STEM education advancement.

Waters has committed to setting science-based emission reduction targets aligned with the SBTi's criteria for a 1.5°C future. Notable achievements include building Massachusetts' first LEED-certified chemical manufacturing facility in 2022 and opening a 45,000 square foot BREEAM Very Good standard facility in the UK's West Midlands with an 'A' rated Energy Performance Certificate.

The DJSI recognition is based on the S&P Global Corporate Sustainability Assessment, which evaluates over 13,000 companies worldwide on industry-specific and financially material sustainability criteria.

Waters (NYSE:WAT) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Udit Batra Ph.D. will engage in a fireside chat on January 13th, 2025, at 2:15 PM Pacific Time. The event will be accessible via live webcast on Waters' Investor Relations website, with replay available for 90 days.

Waters is a global leader in analytical instruments and software, known for innovations in chromatography, mass spectrometry, and thermal analysis. The company serves life, materials, food, and environmental sciences sectors, employing approximately 7,500 people worldwide. Waters maintains direct operations in 35 countries, including 15 manufacturing facilities, with products available in over 100 countries.

Waters (NYSE: WAT) has reported significant progress in its sustainability commitments, exceeding its greenhouse gas emissions reduction target two years ahead of schedule with a 36% reduction from 2016 baseline. The company has achieved notable environmental milestones, including a 50% decrease in landfill waste and a 29% reduction in water use intensity.

In social initiatives, Waters expanded its STEM education efforts through the Waters Student Academy, reaching over 380 students and increasing candidate diversity in recruitment by 6%. The company introduced the University Pathways Program to support career development and diversify talent pipeline.

Waters received recognition as the 2024 Public Company Board of the Year by NACD New England Chapter and was included in Barron's 2024 100 Most Sustainable Companies. The company has committed to science-based emission reduction targets aligned with SBTi's 1.5°C criteria.

Waters (NYSE:WAT) announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO Udit Batra will join a fireside chat on December 4th, 2024, at 10:00 AM Eastern Time. The event will be livestreamed on Waters' Investor Relations website, with a replay available for 90 days.

Waters is a global leader in analytical instruments and software, specializing in chromatography, mass spectrometry, and thermal analysis innovations. The company employs approximately 7,500 people worldwide, operates in 35 countries with 15 manufacturing facilities, and distributes products in over 100 countries.

Waters (NYSE:WAT) has opened a new 45,000 square foot manufacturing facility at Longbridge Business Park, UK. The facility triples the company's manufacturing footprint and enhances machining capacity for components used in mass spectrometry systems. Built to BREEAM Very Good standard with an 'A' Energy Performance Certificate rating, the facility features zero natural gas consumption for heating and maintains temperature-controlled production for sub-micron accuracy manufacturing. The expansion represents a significant investment in the region and supports Waters' Mass Spectrometry Centers in Wilmslow, UK and Wexford, Ireland.

Waters (NYSE: WAT) has announced waters_connect Data Intelligence software, a new cloud-based application designed to enhance laboratory data management and audit readiness. The software integrates with Waters Empower Chromatography Data System (CDS) to provide comprehensive business intelligence on chromatographic data. Key features include real-time audit response capabilities, risk visibility for regulatory compliance, and system suitability monitoring that could help prevent failures estimated to cost up to $600,000 annually. The software will be available for ordering in December 2024.

Waters (NYSE: WAT) reported strong Q3 2024 results with sales of $740 million, up 4% from Q3 2023. The company exceeded guidance across key metrics, with GAAP EPS of $2.71 and non-GAAP EPS of $2.93. All regions and end markets showed growth, with pharmaceutical market sales up 2%, industrial market sales increasing 9%, and academic/government market sales rising 2%. Instrument systems sales grew 1%, while recurring revenues increased 6%. The company raised its full-year 2024 guidance, expecting Q4 constant currency sales growth of 5% to 7%.

Waters (NYSE: WAT) has introduced new bioseparations tools to accelerate and improve the development of RNA-based pharmaceuticals. The comprehensive set includes:

1. Novel digestion enzymes (RapiZyme MC1 and RapiZyme Cusativin) for complete RNA sequence coverage.
2. LC-MS-grade reagents (IonHance HFIP) to increase sensitivity and improve detection accuracy.
3. waters_connect MAP Sequence software for semi-automated workflows, reducing data processing time.

These tools simplify large molecule RNA analysis, supporting the development of mRNA vaccines, personalized cancer therapies, and drugs for genetic disorders. The new products aim to enhance sequence confirmation, modification analysis, and overall characterization of complex RNA molecules, potentially accelerating therapeutic development and lowering barriers for LC-MS non-experts.